Log in

Relevant bibliographies by topics / Multidrug resistance / Journal articles

Journal articles on the topic 'Multidrug resistance'

To see the other types of publications on this topic, follow the link: Multidrug resistance.

Author: Grafiati

Published: 4 June 2021

Last updated: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Multidrug resistance.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sodani, Kamlesh, Atish Patel, Rishil J. Kathawala, and Zhe-Sheng Chen. "Multidrug resistance associated proteins in multidrug resistance." Chinese Journal of Cancer 31, no. 2 (February 5, 2012): 58–72. http://dx.doi.org/10.5732/cjc.011.10329.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pastan, I., and M. M. Gottesman. "Multidrug Resistance." Annual Review of Medicine 42, no. 1 (February 1991): 277–84. http://dx.doi.org/10.1146/annurev.me.42.020191.001425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Tsuruo, Takashi, and Akihiro Tomida. "Multidrug resistance." Anti-Cancer Drugs 6, no. 2 (April 1995): 213–18. http://dx.doi.org/10.1097/00001813-199504000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Tiirikainen, Maarit I., and Tom Krusius. "Multidrug Resistance." Annals of Medicine 23, no. 5 (January 1991): 509–20. http://dx.doi.org/10.3109/07853899109150511.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mickisch, G. H. "Multidrug Resistance." Der Urologe A 35, no. 5 (September 1996): 370–77. http://dx.doi.org/10.1007/s001200050038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Persidis, Aris. "Cancer multidrug resistance." Nature Biotechnology 17, no. 1 (January 1999): 94–95. http://dx.doi.org/10.1038/5289.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gao, Mian, Masayo Yamazaki, Douglas W. Loe, Christopher J. Westlake, Caroline E. Grant, Susan P. C. Cole, and Roger G. Deeley. "Multidrug Resistance Protein." Journal of Biological Chemistry 273, no. 17 (April 24, 1998): 10733–40. http://dx.doi.org/10.1074/jbc.273.17.10733.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Levy, Stuart B. "Confronting Multidrug Resistance." JAMA 269, no. 14 (April 14, 1993): 1840. http://dx.doi.org/10.1001/jama.1993.03500140092042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Brennan, Richard G. "Introduction: multidrug resistance." Seminars in Cell & Developmental Biology 12, no. 3 (June 2001): 201–4. http://dx.doi.org/10.1006/scdb.2000.0245.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ouellette, Marc, and Christoph Kündig. "Microbial multidrug resistance." International Journal of Antimicrobial Agents 8, no. 3 (January 1997): 179–87. http://dx.doi.org/10.1016/s0924-8579(96)00370-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

KUWANO, MICHIHIKO. "Transporter; 7. Multidrug Resistance Transporters: Multidrug Resistance to Anticancer Agents." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 35, no. 2 (2004): 89–96. http://dx.doi.org/10.3999/jscpt.35.2_89.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Lautier, Dominique, Yvan Canitrot, Roger G. Deeley, and Susan P. C. Cole. "Multidrug resistance mediated by the multidrug resistance protein (MRP) gene." Biochemical Pharmacology 52, no. 7 (October 1996): 967–77. http://dx.doi.org/10.1016/0006-2952(96)00450-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Çelik, Cem. "Increasing antimicrobial resistance in nosocomial pathogens; multidrug-resistant extensively drug-resistant and pandrug-resistant Acinetobacter baumannii." Journal of Microbiology and Infectious Diseases 4, no. 1 (March 1, 2014): 7–12. http://dx.doi.org/10.5799/ahinjs.02.2014.01.0116.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Boyanova, Lyudmila, Rumyana Markovska, and Ivan Mitov. "Multidrug resistance in anaerobes." Future Microbiology 14, no. 12 (August 2019): 1055–64. http://dx.doi.org/10.2217/fmb-2019-0132.

Full text

Abstract:

Multidrug resistance (MDR) in anaerobes is not a well-known topic. Bacteroides fragilis group isolates have numerous resistance determinants such as multidrug efflux pumps, cfiA and nimB genes and activating insertion sequences, and some isolates exhibited extensive drug-resistant patterns. MDR rates in B. fragilis group were from 1.5 to >18% and up to >71% in cfiA and nimB positive isolates carrying insertion sequences. MDR was present in >1/2 of Clostridioides difficile isolates, most often in epidemic/hypervirulent strains and unusually high metronidazole or vancomycin resistance has been reported in single studies. MDR was found in Prevotella spp. (in ≤10% of isolates), Finegoldia magna, Veillonella spp. and Cutibacterium acnes. Resistance in the anaerobes tends to be less predictable and anaerobic microbiology is required in more laboratories. New hopes may be new antibiotics such as eravacycline, cadazolid, surotomycin, ridinilazol or C. difficile toxoid vaccines; however, more efforts are needed to track the MDR in anaerobes.

APA, Harvard, Vancouver, ISO, and other styles

15

Kruh, Gary D., and Lori J. Goldstein. "Doxorubicin and multidrug resistance." Current Opinion in Oncology 5, no. 6 (November 1993): 1029–34. http://dx.doi.org/10.1097/00001622-199311000-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Sonneveld, Pieter, and Erik Wiemer. "Inhibitors of multidrug resistance." Current Opinion in Oncology 9, no. 6 (November 1997): 543–48. http://dx.doi.org/10.1097/00001622-199711000-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Holmes, Jon A. "Multidrug Resistance in Leukaemia." Leukemia & Lymphoma 1, no. 3-4 (January 1990): 163–68. http://dx.doi.org/10.3109/10428199009042475.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Nikaido, Hiroshi. "Multidrug Resistance in Bacteria." Annual Review of Biochemistry 78, no. 1 (June 2009): 119–46. http://dx.doi.org/10.1146/annurev.biochem.78.082907.145923.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

MCKENNA, SHARON L., and ROSE ANN PADUA. "MULTIDRUG RESISTANCE IN LEUKAEMIA." British Journal of Haematology 96, no. 4 (March 1997): 659–74. http://dx.doi.org/10.1046/j.1365-2141.1997.d01-2095.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Emini, Emilio A., Donald J. Graham, Leah Gotlib, Jon H. Condra, and Vera W. Byrnes. "HIV and multidrug resistance." Nature 364, no. 6439 (August 1993): 679. http://dx.doi.org/10.1038/364679b0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

BATES, S. E., Z. ZHAN, B. DICKSTEIN, J. S. LEE, S. SCALA, A. T. FOJO, K. PAULL, and W. WILSON. "Reversal of Multidrug Resistance." Journal of Hematotherapy 3, no. 3 (January 1994): 219–23. http://dx.doi.org/10.1089/scd.1.1994.3.219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Mickisch, G. "Multidrug Resistance des Nierenzellkarzinoms." Aktuelle Urologie 25, no. 06 (November 1994): 327–37. http://dx.doi.org/10.1055/s-2008-1058250.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

TWENTYMAN, PETER R. "MODIFIERS OF MULTIDRUG RESISTANCE." British Journal of Haematology 90, no. 4 (August 1995): 735–37. http://dx.doi.org/10.1111/j.1365-2141.1995.tb05189.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Dennis, David T., and James M. Hughes. "Multidrug Resistance in Plague." New England Journal of Medicine 337, no. 10 (September 4, 1997): 702–4. http://dx.doi.org/10.1056/nejm199709043371010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Baik, Seung, and Dong Hoon Lim. "Multidrug Resistance inNeisseria gonorrhoeae." Korean Journal of Urogenital Tract Infection and Inflammation 8, no. 2 (2013): 90. http://dx.doi.org/10.14777/kjutii.2013.8.2.90.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Hall, Andrea M., and C. J. Chang. "Multidrug-Resistance Modulators fromStephaniajaponica." Journal of Natural Products 60, no. 11 (November 1997): 1193–95. http://dx.doi.org/10.1021/np9702042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Gulshan, Kailash, and W. Scott Moye-Rowley. "Multidrug Resistance in Fungi." Eukaryotic Cell 6, no. 11 (September 14, 2007): 1933–42. http://dx.doi.org/10.1128/ec.00254-07.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Leweke, F., M. S. Damian, C. Schindler, and W. Schachenmayr. "Multidrug Resistance in Glioblastoma." Pathology - Research and Practice 194, no. 3 (January 1998): 149–55. http://dx.doi.org/10.1016/s0344-0338(98)80015-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Robert, Jacques, and Christian Jarry. "Multidrug Resistance Reversal Agents." Journal of Medicinal Chemistry 46, no. 23 (November 2003): 4805–17. http://dx.doi.org/10.1021/jm030183a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Chang, Geoffrey. "Multidrug resistance ABC transporters." FEBS Letters 555, no. 1 (October 2, 2003): 102–5. http://dx.doi.org/10.1016/s0014-5793(03)01085-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Baines, Paul, Peter Cumber, and Rose Ann Padua. "Multidrug resistance in leukaemia." Baillière's Clinical Haematology 5, no. 4 (October 1992): 943–60. http://dx.doi.org/10.1016/s0950-3536(11)80053-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Ferry, D. R., and D. J. Kerr. "Multidrug resistance in cancer." BMJ 308, no. 6922 (January 15, 1994): 148–49. http://dx.doi.org/10.1136/bmj.308.6922.148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kaye, SB. "The multidrug resistance phenotype." British Journal of Cancer 58, no. 6 (December 1988): 691–94. http://dx.doi.org/10.1038/bjc.1988.291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Nash, Kevin A. "Multidrug Resistance in Mycobacteria." Current Clinical Microbiology Reports 3, no. 1 (February 13, 2016): 53–61. http://dx.doi.org/10.1007/s40588-016-0032-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Warris, Adilia, Corry M. Weemaes, and Paul E. Verweij. "Multidrug Resistance inAspergillus fumigatus." New England Journal of Medicine 347, no. 26 (December 26, 2002): 2173–74. http://dx.doi.org/10.1056/nejm200212263472618.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Rout, Subhashree, and Rajani Kanta Mahapatra. "Plasmodium falciparum: Multidrug resistance." Chemical Biology & Drug Design 93, no. 5 (February 12, 2019): 737–59. http://dx.doi.org/10.1111/cbdd.13484.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Leith, Catherine. "Multidrug resistance in leukemia." Current Opinion in Hematology 5, no. 4 (1998): 287–91. http://dx.doi.org/10.1097/00062752-199807000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Croop, J. M., P. Gros, and D. E. Housman. "Genetics of multidrug resistance." Journal of Clinical Investigation 81, no. 5 (May 1, 1988): 1303–9. http://dx.doi.org/10.1172/jci113455.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Chabner, B. A., and W. Wilson. "Reversal of multidrug resistance." Journal of Clinical Oncology 9, no. 1 (January 1991): 4–6. http://dx.doi.org/10.1200/jco.1991.9.1.4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Yuen, A. R., and B. I. Sikic. "Multidrug resistance in lymphomas." Journal of Clinical Oncology 12, no. 11 (November 1994): 2453–59. http://dx.doi.org/10.1200/jco.1994.12.11.2453.

Full text

Abstract:

PURPOSE To discuss the significance of multidrug resistance (MDR) in human lymphomas and to review recent and ongoing clinical trials using MDR modulators. DESIGN A medical literature search was used to identify articles that reported results on the expression or modulation of MDR in human lymphomas. This review summarizes the various methods for detecting expression of the mdr1 gene in tumor specimens, the patterns of expression in lymphomas, and recent and upcoming clinical trials using modulating agents to reverse MDR. RESULTS There is considerable variation in the assays used to evaluate the expression of mdr1 in lymphomas. Current methodology includes reverse transcriptase polymerase chain reaction (rt-PCR) for assay of mdr1 mRNA, and immunohistochemistry or flow cytometry for detection of the multidrug transporter, P-glycoprotein (P-gp). The preponderance of evidence suggests that mdr1 expression is relatively low in untreated patients (10% to 20% of lymphomas positive), but increases in patients with recurrent disease (50% to 70% positive). Some evidence suggests that mdr1 expression is a prognostic factor for response to chemotherapy, as well as for subsequent survival. Verapamil and cyclosporine (CsA) have been used as competitive inhibitors of the multidrug transporter P-gp in early clinical trials. Although these studies show some activity in modulating clinical MDR, both verapamil and CsA manifest considerable toxicities at doses below those required for complete inhibition of P-gp function. CONCLUSION MDR due to the expression of the mdr1 gene is an important factor in the course of patients with lymphomas. Continued clinical trials with more potent and less toxic modulators are needed to define the ultimate benefit of modulating MDR in lymphomas.

APA, Harvard, Vancouver, ISO, and other styles

41

Kartner, Norbert, and Victor Ling. "Multidrug Resistance in Cancer." Scientific American 260, no. 3 (March 1989): 44–51. http://dx.doi.org/10.1038/scientificamerican0389-44.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Bradley, Grace, Peter F. Juranka, and Victor Ling. "Mechanism of multidrug resistance." Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 948, no. 1 (August 1988): 87–128. http://dx.doi.org/10.1016/0304-419x(88)90006-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Ferguson, Lynnette R., and Bruce C. Baguley. "Multidrug resistance and mutagenesis." Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 285, no. 1 (January 1993): 79–90. http://dx.doi.org/10.1016/0027-5107(93)90054-j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kaye, S. B. "Reversal of multidrug resistance." Cancer Treatment Reviews 17 (December 1990): 37–43. http://dx.doi.org/10.1016/0305-7372(90)90014-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Kavallaris, Maria. "The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance." Anti-Cancer Drugs 8, no. 1 (January 1997): 17–25. http://dx.doi.org/10.1097/00001813-199701000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Ibrahim, Doa’a Anwar, Al-Akhali A. Al-Akhali A, and Farouk A. Al-Qadasi. "The Prevalence of Antituberculosis Multidrug Resistance in Yemen 2013." International Journal of Scientific Research 3, no. 7 (June 1, 2012): 450–53. http://dx.doi.org/10.15373/22778179/july2014/142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Gottesman, Michael M., Robert W. Robey, and Suresh V. Ambudkar. "New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection." Cancer Drug Resistance 6, no. 3 (2023): 590–5. http://dx.doi.org/10.20517/cdr.2023.86.

Full text

Abstract:

Cancer Drug Resistance publishes contributions to understanding the biology and consequences of mechanisms that interfere with successful treatment of cancer. Since virtually all patients who die of metastatic cancer have multidrug-resistant tumors, improved treatment will require an understanding of the mechanisms of resistance to design therapies that circumvent these mechanisms, exploit these mechanisms, or inactivate these multidrug resistance mechanisms. One example of a resistance mechanism is the expression of ATP-binding cassette efflux pumps, but unfortunately, inhibition of these transporters has not proved to be the solution to overcome multidrug resistance in cancer. Other mechanisms that confer multidrug resistance, and the confluence of multiple different mechanisms (multifactorial multidrug resistance) have been identified, and it is the goal of this Special Collection to expand this catalog of potential multidrug resistance mechanisms, to explore novel ways to overcome resistance, and to present thoughtful reviews on the problem of multidrug resistance in cancer.

APA, Harvard, Vancouver, ISO, and other styles

48

Weisburg, J. H., M. Curcio, P. C. Caron, G. Raghu, E. B. Mechetner, P. D. Roepe, and D. A. Scheinberg. "The multidrug resistance phenotype confers immunological resistance." Journal of Experimental Medicine 183, no. 6 (June 1, 1996): 2699–704. http://dx.doi.org/10.1084/jem.183.6.2699.

Full text

Abstract:

Multidrug resistance (MDR), which is due, in part, to the overexpression of P-glycoprotein, confers resistance to a variety of natural product chemotherapeutic agents such as daunorubicin, vincristine, and colchicine. RV+ cells are a P-glycoprotein overexpressing variant of the HL60 myeloid leukemia cell line. In addition to classic MDR, RV+ cells displayed relative resistance to complement-mediated cytotoxicity with both immunoglobulin G and M antibodies against different cell surface antigens, but not to antibody-dependent cellular cytotoxicity and lymphokine-activated killing. Complement resistance was reversed both by treatment with verapamil and with specific monoclonal antibodies (mAbs) capable of binding to P-glycoprotein and blocking its function. To further confirm that the resistance of RV+ cells was not a consequence of the selection of the cells on vincristine, a second system involving P-glycoprotein infectants was also investigated. K562 cells infected with the MDR1 gene, which were never selected on chemotherapeutic drugs, also displayed relative resistance to complement-mediated cytotoxicity. This MDR1 infection-induced resistance was also reversed by mAbs that bind to P-glycoprotein. Therefore, the MDR phenotype as mediated by P-glycoprotein provides resistance to complement-mediated cytotoxicity. The increased intracellular pH and the decreased membrane potential due to the MDR phenotype may result in abnormal membrane attack complex function. This observation may have implications for the possible mechanisms of action of P-glycoprotein and for a possible physiologic role for P-glycoprotein in protection against complement-mediated autolysis.

APA, Harvard, Vancouver, ISO, and other styles

49

Wang, Jing-Quan, Yuqi Yang, Chao-Yun Cai, Qiu-Xu Teng, Qingbin Cui, Jun Lin, Yehuda G. Assaraf, and Zhe-Sheng Chen. "Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance." Drug Resistance Updates 54 (January 2021): 100743. http://dx.doi.org/10.1016/j.drup.2021.100743.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Zhao, Lihua, Yanhui Sun, Xiaoqing Li, Xianqing Jin, Youhua Xu, Zhenhua Guo, Rui Liang, Xionghui Ding, Tingfu Chen, and Siqi Wang. "Multidrug resistance strength of the novel multidrug resistance gene HA117: compared with MRP1." Medical Oncology 28, no. 4 (July 16, 2010): 1188–95. http://dx.doi.org/10.1007/s12032-010-9624-y.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!